NCT03695744 2023-07-10
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
Phase 2 Unknown
Clinical Trials
12 trialsNCT05218603 2022-09-16
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
PETHEMA Foundation
Unknown
NCT04474938 2022-05-10
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03669445 2020-07-30
IFM2018-01
University Hospital, Toulouse
Phase 2 Unknown
NCT04065308 2019-08-22
Dara_DCEP
Seoul National University Hospital
Phase 2 Unknown
NCT03757221 2019-07-08
IDARA
University Hospital, Caen
Phase 2 Unknown
NCT03992170 2019-06-20
DART4MM
Azienda Ospedaliera Universitaria Senese
Phase 2 Unknown
NCT03697655 2019-01-03
PREDATOR
Polish Myeloma Consortium
Phase 2 Unknown
NCT03746652 2018-11-23
DARIA
Hellenic Society of Hematology
Phase 2 Unknown
NCT03143036 2018-06-07
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
National University Hospital, Singapore
Phase 2 Unknown
NCT02955810 2018-03-29
CyBorD-Dara
National University of Ireland, Galway, Ireland
Phase 1 Unknown
NCT03475628 2018-03-23
REBUILD
Hellenic Society of Hematology
Phase 2 Unknown